Evidence map›Paper›PMID 36467505›Full record

ArticleJournal of oncology2022

Development and Validation of a Combined Ferroptosis and Immune Prognostic Model for Melanoma.

Mingsui Tang, Yaling Li, Fang Wang, Jiande Han, Yali Gao

Open access · hybridAbstract read
In one paragraph

Article in Journal of oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 75% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Mingsui TangDepartment of Dermatology, The First Hospital of China Medical University, Shenyang 110001, Liaoning, China.ORCID https://orcid.org/0000-0003-2961-9213
Yaling LiDepartment of Dermatology, The First Hospital of China Medical University, Shenyang 110001, Liaoning, China.ORCID https://orcid.org/0000-0001-9136-4990
Fang WangDepartment of Dermatology, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou 510080, Guangdong, China.ORCID https://orcid.org/0000-0002-3327-4177
Jiande HanDepartment of Dermatology, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou 510080, Guangdong, China.ORCID https://orcid.org/0000-0002-4465-7632
Yali GaoDepartment of Dermatology, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou 510080, Guangdong, China.ORCID https://orcid.org/0000-0002-5511-9282
Sun Yat-sen University · CNFirst Hospital of China Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Melanoma development and progression are significantly influenced by ferroptosis and the immune microenvironment. However, there are no reliable biomarkers for melanoma prognosis prediction based on ferroptosis and immunological response. Methods: Ferroptosis-related genes (FRGs) were retrieved from the FerrDb website. Immune-related genes (IRGs) were collected in the ImmPort dataset. The TCGA (The Cancer Genome Atlas) and GSE65904 datasets both contained prognostic FRGs and IRGs. The model was created using multivariate Cox regression, the least absolute shrinkage and selection operator (LASSO) Cox regression analysis, and the analysis and comparison between the expression patterns of ferroptosis and immune cell infiltration were done. Last but not least, research was conducted to assess the expression and involvement of the genes in the comprehensive index of ferroptosis and immune (CIFI). Results: Two prognostic ferroptosis- and immune-related markers ( Conclusion: In this study, a novel prognostic classifier for melanoma patients was developed and validated using ferroptosis and immune expression profiles.

Identifiers

PMID36467505
PMCPMC9715341
OpenAlexW4309918515

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.